Targeted Therapy for the Central Nervous System: Formulation, Clinical Challenges, and Regulatory Strategies presents research on various delivery methods of drugs to the central nervous system and brain. This volume examines targeted therapies for neurodegenerative disorders and succinctly outlines the future of drug delivery systems, highlighting significant advancements specifically relating to central nervous system delivery. This book will be of great interest to researchers working in the field of neuroscience and pharmacology as well as clinicians (pharmacists, radiologists, psychiatrists).…mehr
Targeted Therapy for the Central Nervous System: Formulation, Clinical Challenges, and Regulatory Strategies presents research on various delivery methods of drugs to the central nervous system and brain. This volume examines targeted therapies for neurodegenerative disorders and succinctly outlines the future of drug delivery systems, highlighting significant advancements specifically relating to central nervous system delivery. This book will be of great interest to researchers working in the field of neuroscience and pharmacology as well as clinicians (pharmacists, radiologists, psychiatrists).Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Part I. Brief About Pathophysiology 1. Etiology and Treatment Challenges for Neurodegenerative Disorders 2. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric Disorders 3. Barriers to Progress of Neurotherapeutics: Getting Drugs to the Brain Part II. Novel Formulation Strategies for Targeted Therapy 4. IGF-II Conjugated Nanocarrier for Brain Targeting 5. ApoE Potential in CNS Drugs Targeting and as CNS Therapeutic 6. Transferrin Functionalized Nanoparticles for Targeted Drug Delivery in Biological Systems 7. Surface Engineered Multimodal Magnetic Nanoparticles for Neurodegenerative Diseases 8. Tau Targeting Biomimetic Nanoparticles 9. Stem Cell Therapy as a Novel Concept to Combat CNS Disorders 10. SR-B1 Receptor Targeting in CNS Disorders 11. ß- and ¿-secretases as Therapeutic Targets for Alzheimer’s Disease 12. Minimally Invasive Nasal Depot (MIND) Technique for Direct BDNF AntagoNAT Delivery to the Brain 13. Immunosuppressive and Immunomodulatory Therapies 14. CRISPR/Cas9 Gene Editing: A New Hope for Alzheimer’s Disease 15. Artificial Intelligence: Ways and Means for Central Nervous System (CNS) Delivery 16. Carbon Dots as Versatile Nano-architectures for the Treatment of Neurological Disorders Part III. Clinical Challenges and Regulatory Updates 17. Animal Models for Clinical Evaluation 18. Medical Device Contributors: Abhishek Swarnkar, Viral Patel, Amit Patel, Manan Raval 19. Regulation of Nanomaterials and Nanomedicines for Clinical Applications 20. Regulatory Considerations for the use of Biomarkers and Personalized Medicine in CNS Drug Development 21. Regulatory Toxicology Testing for Pharmaceuticals 22. Emerging Challenges and Opportunities for Drug and Drug Product Registrations 23. CRISPR/Cas9 Gene Editing: A New Hope for Parkinson’s Disease
Part I. Brief About Pathophysiology 1. Etiology and Treatment Challenges for Neurodegenerative Disorders 2. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric Disorders 3. Barriers to Progress of Neurotherapeutics: Getting Drugs to the Brain Part II. Novel Formulation Strategies for Targeted Therapy 4. IGF-II Conjugated Nanocarrier for Brain Targeting 5. ApoE Potential in CNS Drugs Targeting and as CNS Therapeutic 6. Transferrin Functionalized Nanoparticles for Targeted Drug Delivery in Biological Systems 7. Surface Engineered Multimodal Magnetic Nanoparticles for Neurodegenerative Diseases 8. Tau Targeting Biomimetic Nanoparticles 9. Stem Cell Therapy as a Novel Concept to Combat CNS Disorders 10. SR-B1 Receptor Targeting in CNS Disorders 11. ß- and ¿-secretases as Therapeutic Targets for Alzheimer’s Disease 12. Minimally Invasive Nasal Depot (MIND) Technique for Direct BDNF AntagoNAT Delivery to the Brain 13. Immunosuppressive and Immunomodulatory Therapies 14. CRISPR/Cas9 Gene Editing: A New Hope for Alzheimer’s Disease 15. Artificial Intelligence: Ways and Means for Central Nervous System (CNS) Delivery 16. Carbon Dots as Versatile Nano-architectures for the Treatment of Neurological Disorders Part III. Clinical Challenges and Regulatory Updates 17. Animal Models for Clinical Evaluation 18. Medical Device Contributors: Abhishek Swarnkar, Viral Patel, Amit Patel, Manan Raval 19. Regulation of Nanomaterials and Nanomedicines for Clinical Applications 20. Regulatory Considerations for the use of Biomarkers and Personalized Medicine in CNS Drug Development 21. Regulatory Toxicology Testing for Pharmaceuticals 22. Emerging Challenges and Opportunities for Drug and Drug Product Registrations 23. CRISPR/Cas9 Gene Editing: A New Hope for Parkinson’s Disease
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
